Clinical Trials


ProTECT III: Progesterone for the Treatment of Traumatic Brain Injury

The results from the ProTECTIII trial comparing intravenous progesterone to placebo for the treatment of a moderate to severe traumatic brain injury (TBI) are out. While traumatic brain injury (TBI) is a huge problem and an estimated 52,000 people will die every year from one and cost Americans tens of billions of dollars a year between treatment and disability, scientists have not been able to come up with a drug treatment that works for TBI in over 30 years. Disappointingly, the ProTECT results – which were published in the December 10, 2014, issue of the New England Journal of Medicine – show that the treatment of acute traumatic brain injury with the hormone progesterone provides no significant benefit to patients when compared with placebo. The preclinical data on progesterone’s brain protective effects are compelling, but this was not able to be shown in a large trial with humans who have traumatic brain injury. To learn more about the ProTECT trial results, visit the ProTECT website at: Hurley Medical Center was one site for this study.